HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Yang, Song; Xing, Huichun; Wang, Yuming; Hou, Jinlin; Luo, Dan; Xie, Qing; Ning, Qin; Ren, Hong; Ding, Huiguo; Sheng, Jifang; Wei, Lai; Chen, Shijun; Fan, Xin; Huang, Wenxiang; Chen, Pan; Gao, Zhiliang; Zhang, Jiming; Zhou, Boping; Chen, Guofeng; Wan, Mo-Bin; Tang, Hong; Wang, Guiqiang; Yang, Yue; Xu, Da; Dong, Paul R; Wang, Qi-xin; Wang, Jue; Bognar, Fernando Alvarez; Xu, Dao-zhen; Cheng, Jun

doi:10.1186/s12985-016-0640-1

Cited by 7 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biochemical, virological and serological values and dynamics measured during treatment can also predict HBV DNA, HBeAg and HBsAg responses in patients treated with peg‐IFN‐α–based regimens. Patients with an alanine transaminase (ALT) elevation greater than 5 times the baseline value, HBsAg levels < 1500 IU/mL and HBV DNA levels < 10 000 copies/mL (or 2000 IU/mL) at 12 and 24 weeks of treatment were more likely to achieve HBeAg seroconversion and a sustained off‐treatment virological response after continued peg‐IFN‐α–based treatment to 48 weeks . Those with ALT elevation and an HBsAg decline from baseline >1 log at 12 weeks of treatment were more likely to achieve HBsAg loss .…”

Section: Efficacy Of Peg‐ifnα−containing Regimens In Achieving a Funcmentioning

confidence: 99%

“…Patients with an alanine transaminase (ALT) elevation greater than 5 times the baseline value, 11 HBsAg levels < 1500 IU/mL and HBV DNA levels < 10 000 copies/mL (or 2000 IU/mL) at 12 and 24 weeks of treatment were more likely to achieve HBeAg seroconversion and a sustained off-treatment virological response after continued peg-IFNα-based treatment to 48 weeks. 16,17,23,[35][36][37] Those with ALT elevation and an HBsAg decline from baseline >1 log at 12 weeks of treatment were more likely to achieve HBsAg loss. 13 HBV genotype A/D patients without an HBsAg decline at week 12, HBV genotype B/C patients with HBsAg levels still >20 000 IU/ mL at week 12, or all HBV genotypes patients with HBsAg levels >20 000 IU/mL or an HBV DNA decline < 2 log IU/mL at week 24 of treatment were less likely to achieve HBeAg seroconversion and an eventual sustained virological response.…”

Section: Selection Of Treatment-naïve Patients Who Are More Likely mentioning

confidence: 99%

See 1 more Smart Citation

Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

Ren

Huang

2019

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Chronic hepatitis B virus (HBV) infection continues to pose a serious global health threat and a significant socio‐economic burden in many areas of the world. Almost all current clinical practice guidelines on the management of chronic hepatitis B (CHB) infection recommend that eligible patients pursue the optimal treatment endpoint, which is defined as HBsAg loss with or without anti‐HBs seroconversion. This review describes the effects of various regimens containing pegylated interferon (peg‐IFN)‐alpha on functional cure and the outcome of hepatocellular carcinoma (HCC) in patients with CHB. Peg‐IFN‐α monotherapy is a treatment option recommended by local and international clinical practice guidelines to help more CHB patients achieve a sustained off‐treatment virological response, which is particularly appropriate for relatively young patients who demand a finite treatment approach. Peg‐IFN‐α add‐on or sequential therapy in patients who have achieved a suppressed viral load after nucleos(t)ide analog (NA) therapy may offer further benefits on HBeAg seroconversion and HBsAg decline, although the effects of de novo combination therapy with peg‐IFN‐α and NAs on long‐term outcomes remain unclear. Evaluation of baseline and on‐treatment predictors is useful for selecting the patients who are likely to achieve additional benefits. Furthermore, some recent studies have shown that peg‐IFN‐α–based therapy results in better prevention of HBV‐related hepatocellular carcinoma (HCC), especially in high‐risk patients.

show abstract

Section: Efficacy Of Peg‐ifnα−containing Regimens In Achieving a Funcmentioning

confidence: 99%

Section: Selection Of Treatment-naïve Patients Who Are More Likely mentioning

confidence: 99%

Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

Ren

Huang

2019

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Ji et all reported that 87.5% and 75% of patients with a decrease in HBeAg > 2 logs have undetectable HBV DNA and HBeAg seroconversion, respectively (Ji et al, 2013). Previous studies revealed that its levels were more consistently associated with HBeAg seroconversion than that of HBV DNA (Fried et al, 2008;Yang et al, 2016). Furthermore, its quantification during therapy also has a good prediction of HBV DNA suppression with Peg-IFN therapy.…”

Section: Discussionmentioning

confidence: 94%

Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate

et al. 2022

View full text Add to dashboard Cite

Background: This study aims to determine the factors affecting HBV DNA suppression in chronic hepatitis B patients with tenofovir disoproxil fumarate (TDF). Methods: A case-control was carried out from October 2021 to August 2022 on 182 chronic hepatitis B patients who had TDF therapy regularly for 24 weeks at H. Adam Malik and USU Hospitals in Medan, Indonesia. The history of the samples was obtained, followed by physical examination, and blood collection. CTLA-4 polymorphism examination was carried out using real-time PCR, while the serum CTLA-4 levels were assessed with ELISA. Results: The results showed that CTLA-4, HBV DNA, ALT, and CTLA-4 -1661G>A polymorphisms have a relationship with HBV DNA suppression in chronic hepatitis B patients with TDF. Conclusions: The levels of CTLA-4, HBV DNA, ALT, and CTLA-4 -1661G>A polymorphism have a potential relationship with the suppression of HBV DNA in chronic hepatitis B patients with TDF.

show abstract

“…Song et al showed that on-treatment HBsAg quantification predicted off-treatment CR (HBeAg seroconversion combined with HBV DNA level <2000 IU/mL) after 48 weeks of PEG-IFN therapy. 14 Based on a total of 474 IFN-α treated HBeAg-positive CHB patients, Mao et al demonstrated that ALT, HBV DNA level, AST, HBV genotype, activity grading (G) of intrahepatic inflammation, score (S) of liver fibrosis, age and gender were the most significant baseline predictive factors. 15 Wang et al also reported that baseline ALT level was associated with HBeAg seroconversion, while baseline HBsAg levels of <250 IU/mL and HBV DNA <2.5 × 10 7 IU/mL were strongly associated with sustained off-treatment response.…”

Section: Discussionmentioning

confidence: 99%

Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients

Zhu¹,

Li²,

Xu³

et al. 2022

IJGM

View full text Add to dashboard Cite

Introduction The adaptive immune response may reflect the immunomodulatory efficacy during peginterferon alfa-2a (PEG-IFN α-2a) treatment in chronic hepatitis B (CHB) patients. We evaluated the predictive efficiency of T-cell subsets on patient’s response to PEG-IFN α-2a treatment. Methods The proportions of CD8 + PD-1 + , CD8 + Tim-3 + and CD4 + CD25 high T-cells were measured at baseline and week 52 in CHB patients who underwent PEG-IFN α-2a treatment. The proportions of T-cell subsets were compared among different responders and non-responders (determined by biochemical, serological, and virological responses). Results The baseline proportions of the three T-cell subsets were significantly higher in CHB patients (65 cases) than in healthy controls (28 cases), while the proportions declined significantly after 52 weeks of PEG-IFN treatment. Responders (ALT < 40 IU/L, 89.2% [58/65]; HBV DNA < 2.7 log10 IU/ml, 66.2% [43/65]; and HBeAg seroconversion [SR], 53.9% [35/65]) experienced more pronounced declines in the proportion of T-cell subsets compared to non-responders. In particular, the baseline proportions of CD4 + CD25 high T-cells displayed significant difference between SR and non-SR groups. The stepwise logistic regression analysis identified that CD4 + CD25 high T-cells combined with baseline HBV DNA and ALT can predict SR and CR (ALT < 40 IU/L, HBV DNA < 2.7 log10 IU/mL and HBeAg seroconversion) after 52 weeks of PEG-IFN treatment with high accuracy. Conclusion PEG-IFN therapy induces significant declines in the proportion of some key T-cell subsets in HBeAg-positive patients. The model constructed with CD4 + CD25 high T-cells combined with ATL and HBV DNA may help to predict the efficacy of PEG-IFN α-2a therapy.

show abstract

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

Cited by 7 publications

References 31 publications

Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

Effects of pegylated interferon‐α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B

Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate

Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients

Contact Info

Product

Resources

About